Clinical impact of primary tumor sidedness and sex on unresectable post-recurrence survival in resected pathological stage II-III colorectal cancers: a nationwide multicenter retrospective study
Background Several studies have demonstrated that right-sided tumors have poorer prognosis than left-sided tumors in patients with unresectable colorectal cancer (CRC). The predictive ability of the tumor sidedness in CRC treated with chemotherapy in each sex is unclear. Methods Subjects were 964 un...
Saved in:
Published in | BMC Cancer Vol. 22; no. 1; pp. 486 - 10 |
---|---|
Main Authors | , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
London
Springer Science and Business Media LLC
02.05.2022
BioMed Central BioMed Central Ltd BMC |
Subjects | |
Online Access | Get full text |
ISSN | 1471-2407 1471-2407 |
DOI | 10.1186/s12885-022-09615-z |
Cover
Abstract | Background
Several studies have demonstrated that right-sided tumors have poorer prognosis than left-sided tumors in patients with unresectable colorectal cancer (CRC). The predictive ability of the tumor sidedness in CRC treated with chemotherapy in each sex is unclear.
Methods
Subjects were 964 unresectable recurrent patients treated with chemotherapy with stage II-III CRC after curative resection between 2004 and 2012. Post-recurrence cancer-specific survival (CSS) for each sex was examined.
Results
Patients were 603 males (222 right-side tumors (cecum to transverse colon) and 381 left-sided tumors (descending colon to rectum)), and 361 females (167 right-side tumors and 194 left-sided tumors). Right-sided tumors developed peritoneal recurrences in males and females. Left-sided tumors were associated with locoregional recurrences in males and with lung recurrences in females. Right-sided tumors were associated with shorter post-recurrence CSS in both sexes. In males, multivariate analyses showed that right-sided tumors were associated with shorter post-recurrence CSS (HR: 1.53,
P
< 0.0001) together with the presence of regional lymph node metastasis histopathological type of other than differentiated adenocarcinoma, the recurrence of liver only, the recurrence of peritoneal dissemination only, and relapse-free interval less than one-year. In females, multivariate analyses showed that right-sided tumors were associated with shorter post-recurrence CSS (HR: 1.50,
P
= 0.0019) together with advanced depth of invasion, the presence of regional lymph node metastasis, and recurrence of liver only.
Conclusions
Primary tumor sidedness in both sexes in unresectable recurrent CRC patients treated with chemotherapy may have prognostic implications for post-recurrence CSS. |
---|---|
AbstractList | Several studies have demonstrated that right-sided tumors have poorer prognosis than left-sided tumors in patients with unresectable colorectal cancer (CRC). The predictive ability of the tumor sidedness in CRC treated with chemotherapy in each sex is unclear. Subjects were 964 unresectable recurrent patients treated with chemotherapy with stage II-III CRC after curative resection between 2004 and 2012. Post-recurrence cancer-specific survival (CSS) for each sex was examined. Primary tumor sidedness in both sexes in unresectable recurrent CRC patients treated with chemotherapy may have prognostic implications for post-recurrence CSS. Abstract Background Several studies have demonstrated that right-sided tumors have poorer prognosis than left-sided tumors in patients with unresectable colorectal cancer (CRC). The predictive ability of the tumor sidedness in CRC treated with chemotherapy in each sex is unclear. Methods Subjects were 964 unresectable recurrent patients treated with chemotherapy with stage II-III CRC after curative resection between 2004 and 2012. Post-recurrence cancer-specific survival (CSS) for each sex was examined. Results Patients were 603 males (222 right-side tumors (cecum to transverse colon) and 381 left-sided tumors (descending colon to rectum)), and 361 females (167 right-side tumors and 194 left-sided tumors). Right-sided tumors developed peritoneal recurrences in males and females. Left-sided tumors were associated with locoregional recurrences in males and with lung recurrences in females. Right-sided tumors were associated with shorter post-recurrence CSS in both sexes. In males, multivariate analyses showed that right-sided tumors were associated with shorter post-recurrence CSS (HR: 1.53, P < 0.0001) together with the presence of regional lymph node metastasis histopathological type of other than differentiated adenocarcinoma, the recurrence of liver only, the recurrence of peritoneal dissemination only, and relapse-free interval less than one-year. In females, multivariate analyses showed that right-sided tumors were associated with shorter post-recurrence CSS (HR: 1.50, P = 0.0019) together with advanced depth of invasion, the presence of regional lymph node metastasis, and recurrence of liver only. Conclusions Primary tumor sidedness in both sexes in unresectable recurrent CRC patients treated with chemotherapy may have prognostic implications for post-recurrence CSS. Background Several studies have demonstrated that right-sided tumors have poorer prognosis than left-sided tumors in patients with unresectable colorectal cancer (CRC). The predictive ability of the tumor sidedness in CRC treated with chemotherapy in each sex is unclear. Methods Subjects were 964 unresectable recurrent patients treated with chemotherapy with stage II-III CRC after curative resection between 2004 and 2012. Post-recurrence cancer-specific survival (CSS) for each sex was examined. Results Patients were 603 males (222 right-side tumors (cecum to transverse colon) and 381 left-sided tumors (descending colon to rectum)), and 361 females (167 right-side tumors and 194 left-sided tumors). Right-sided tumors developed peritoneal recurrences in males and females. Left-sided tumors were associated with locoregional recurrences in males and with lung recurrences in females. Right-sided tumors were associated with shorter post-recurrence CSS in both sexes. In males, multivariate analyses showed that right-sided tumors were associated with shorter post-recurrence CSS (HR: 1.53, P < 0.0001) together with the presence of regional lymph node metastasis histopathological type of other than differentiated adenocarcinoma, the recurrence of liver only, the recurrence of peritoneal dissemination only, and relapse-free interval less than one-year. In females, multivariate analyses showed that right-sided tumors were associated with shorter post-recurrence CSS (HR: 1.50, P = 0.0019) together with advanced depth of invasion, the presence of regional lymph node metastasis, and recurrence of liver only. Conclusions Primary tumor sidedness in both sexes in unresectable recurrent CRC patients treated with chemotherapy may have prognostic implications for post-recurrence CSS. Several studies have demonstrated that right-sided tumors have poorer prognosis than left-sided tumors in patients with unresectable colorectal cancer (CRC). The predictive ability of the tumor sidedness in CRC treated with chemotherapy in each sex is unclear. Subjects were 964 unresectable recurrent patients treated with chemotherapy with stage II-III CRC after curative resection between 2004 and 2012. Post-recurrence cancer-specific survival (CSS) for each sex was examined. Patients were 603 males (222 right-side tumors (cecum to transverse colon) and 381 left-sided tumors (descending colon to rectum)), and 361 females (167 right-side tumors and 194 left-sided tumors). Right-sided tumors developed peritoneal recurrences in males and females. Left-sided tumors were associated with locoregional recurrences in males and with lung recurrences in females. Right-sided tumors were associated with shorter post-recurrence CSS in both sexes. In males, multivariate analyses showed that right-sided tumors were associated with shorter post-recurrence CSS (HR: 1.53, P < 0.0001) together with the presence of regional lymph node metastasis histopathological type of other than differentiated adenocarcinoma, the recurrence of liver only, the recurrence of peritoneal dissemination only, and relapse-free interval less than one-year. In females, multivariate analyses showed that right-sided tumors were associated with shorter post-recurrence CSS (HR: 1.50, P = 0.0019) together with advanced depth of invasion, the presence of regional lymph node metastasis, and recurrence of liver only. Primary tumor sidedness in both sexes in unresectable recurrent CRC patients treated with chemotherapy may have prognostic implications for post-recurrence CSS. Background Several studies have demonstrated that right-sided tumors have poorer prognosis than left-sided tumors in patients with unresectable colorectal cancer (CRC). The predictive ability of the tumor sidedness in CRC treated with chemotherapy in each sex is unclear. Methods Subjects were 964 unresectable recurrent patients treated with chemotherapy with stage II-III CRC after curative resection between 2004 and 2012. Post-recurrence cancer-specific survival (CSS) for each sex was examined. Results Patients were 603 males (222 right-side tumors (cecum to transverse colon) and 381 left-sided tumors (descending colon to rectum)), and 361 females (167 right-side tumors and 194 left-sided tumors). Right-sided tumors developed peritoneal recurrences in males and females. Left-sided tumors were associated with locoregional recurrences in males and with lung recurrences in females. Right-sided tumors were associated with shorter post-recurrence CSS in both sexes. In males, multivariate analyses showed that right-sided tumors were associated with shorter post-recurrence CSS (HR: 1.53, P < 0.0001) together with the presence of regional lymph node metastasis histopathological type of other than differentiated adenocarcinoma, the recurrence of liver only, the recurrence of peritoneal dissemination only, and relapse-free interval less than one-year. In females, multivariate analyses showed that right-sided tumors were associated with shorter post-recurrence CSS (HR: 1.50, P = 0.0019) together with advanced depth of invasion, the presence of regional lymph node metastasis, and recurrence of liver only. Conclusions Primary tumor sidedness in both sexes in unresectable recurrent CRC patients treated with chemotherapy may have prognostic implications for post-recurrence CSS. Keywords: Primary tumor location, Prognostic marker, Colorectal cancer, Chemoradiotherapy, Outcome Background Several studies have demonstrated that right-sided tumors have poorer prognosis than left-sided tumors in patients with unresectable colorectal cancer (CRC). The predictive ability of the tumor sidedness in CRC treated with chemotherapy in each sex is unclear. Methods Subjects were 964 unresectable recurrent patients treated with chemotherapy with stage II-III CRC after curative resection between 2004 and 2012. Post-recurrence cancer-specific survival (CSS) for each sex was examined. Results Patients were 603 males (222 right-side tumors (cecum to transverse colon) and 381 left-sided tumors (descending colon to rectum)), and 361 females (167 right-side tumors and 194 left-sided tumors). Right-sided tumors developed peritoneal recurrences in males and females. Left-sided tumors were associated with locoregional recurrences in males and with lung recurrences in females. Right-sided tumors were associated with shorter post-recurrence CSS in both sexes. In males, multivariate analyses showed that right-sided tumors were associated with shorter post-recurrence CSS (HR: 1.53, P < 0.0001) together with the presence of regional lymph node metastasis histopathological type of other than differentiated adenocarcinoma, the recurrence of liver only, the recurrence of peritoneal dissemination only, and relapse-free interval less than one-year. In females, multivariate analyses showed that right-sided tumors were associated with shorter post-recurrence CSS (HR: 1.50, P = 0.0019) together with advanced depth of invasion, the presence of regional lymph node metastasis, and recurrence of liver only. Conclusions Primary tumor sidedness in both sexes in unresectable recurrent CRC patients treated with chemotherapy may have prognostic implications for post-recurrence CSS. Several studies have demonstrated that right-sided tumors have poorer prognosis than left-sided tumors in patients with unresectable colorectal cancer (CRC). The predictive ability of the tumor sidedness in CRC treated with chemotherapy in each sex is unclear.BACKGROUNDSeveral studies have demonstrated that right-sided tumors have poorer prognosis than left-sided tumors in patients with unresectable colorectal cancer (CRC). The predictive ability of the tumor sidedness in CRC treated with chemotherapy in each sex is unclear.Subjects were 964 unresectable recurrent patients treated with chemotherapy with stage II-III CRC after curative resection between 2004 and 2012. Post-recurrence cancer-specific survival (CSS) for each sex was examined.METHODSSubjects were 964 unresectable recurrent patients treated with chemotherapy with stage II-III CRC after curative resection between 2004 and 2012. Post-recurrence cancer-specific survival (CSS) for each sex was examined.Patients were 603 males (222 right-side tumors (cecum to transverse colon) and 381 left-sided tumors (descending colon to rectum)), and 361 females (167 right-side tumors and 194 left-sided tumors). Right-sided tumors developed peritoneal recurrences in males and females. Left-sided tumors were associated with locoregional recurrences in males and with lung recurrences in females. Right-sided tumors were associated with shorter post-recurrence CSS in both sexes. In males, multivariate analyses showed that right-sided tumors were associated with shorter post-recurrence CSS (HR: 1.53, P < 0.0001) together with the presence of regional lymph node metastasis histopathological type of other than differentiated adenocarcinoma, the recurrence of liver only, the recurrence of peritoneal dissemination only, and relapse-free interval less than one-year. In females, multivariate analyses showed that right-sided tumors were associated with shorter post-recurrence CSS (HR: 1.50, P = 0.0019) together with advanced depth of invasion, the presence of regional lymph node metastasis, and recurrence of liver only.RESULTSPatients were 603 males (222 right-side tumors (cecum to transverse colon) and 381 left-sided tumors (descending colon to rectum)), and 361 females (167 right-side tumors and 194 left-sided tumors). Right-sided tumors developed peritoneal recurrences in males and females. Left-sided tumors were associated with locoregional recurrences in males and with lung recurrences in females. Right-sided tumors were associated with shorter post-recurrence CSS in both sexes. In males, multivariate analyses showed that right-sided tumors were associated with shorter post-recurrence CSS (HR: 1.53, P < 0.0001) together with the presence of regional lymph node metastasis histopathological type of other than differentiated adenocarcinoma, the recurrence of liver only, the recurrence of peritoneal dissemination only, and relapse-free interval less than one-year. In females, multivariate analyses showed that right-sided tumors were associated with shorter post-recurrence CSS (HR: 1.50, P = 0.0019) together with advanced depth of invasion, the presence of regional lymph node metastasis, and recurrence of liver only.Primary tumor sidedness in both sexes in unresectable recurrent CRC patients treated with chemotherapy may have prognostic implications for post-recurrence CSS.CONCLUSIONSPrimary tumor sidedness in both sexes in unresectable recurrent CRC patients treated with chemotherapy may have prognostic implications for post-recurrence CSS. |
ArticleNumber | 486 |
Audience | Academic |
Author | Shinya Abe Hiroyuki Anzai Soichiro Ishihara Hirofumi Sonoda Kazushige Kawai Yuzo Nagai Kenichi Sugihara Shinichi Yamauchi Hiroaki Nozawa Shigenobu Emoto Yuichiro Yokoyama Kazuhito Sasaki Tsuyoshi Ozawa Koji Murono |
Author_xml | – sequence: 1 givenname: Shinya surname: Abe fullname: Abe, Shinya email: sa61451689@gmail.com organization: Department of Surgical Oncology, Graduate School of Medicine, The University of Tokyo – sequence: 2 givenname: Kazushige surname: Kawai fullname: Kawai, Kazushige organization: Department of Surgical Oncology, Graduate School of Medicine, The University of Tokyo – sequence: 3 givenname: Hiroaki surname: Nozawa fullname: Nozawa, Hiroaki organization: Department of Surgical Oncology, Graduate School of Medicine, The University of Tokyo – sequence: 4 givenname: Kazuhito surname: Sasaki fullname: Sasaki, Kazuhito organization: Department of Surgical Oncology, Graduate School of Medicine, The University of Tokyo – sequence: 5 givenname: Koji surname: Murono fullname: Murono, Koji organization: Department of Surgical Oncology, Graduate School of Medicine, The University of Tokyo – sequence: 6 givenname: Shigenobu surname: Emoto fullname: Emoto, Shigenobu organization: Department of Surgical Oncology, Graduate School of Medicine, The University of Tokyo – sequence: 7 givenname: Tsuyoshi surname: Ozawa fullname: Ozawa, Tsuyoshi organization: Department of Surgical Oncology, Graduate School of Medicine, The University of Tokyo – sequence: 8 givenname: Yuichiro surname: Yokoyama fullname: Yokoyama, Yuichiro organization: Department of Surgical Oncology, Graduate School of Medicine, The University of Tokyo – sequence: 9 givenname: Yuzo surname: Nagai fullname: Nagai, Yuzo organization: Department of Surgical Oncology, Graduate School of Medicine, The University of Tokyo – sequence: 10 givenname: Hiroyuki surname: Anzai fullname: Anzai, Hiroyuki organization: Department of Surgical Oncology, Graduate School of Medicine, The University of Tokyo – sequence: 11 givenname: Hirofumi surname: Sonoda fullname: Sonoda, Hirofumi organization: Department of Surgical Oncology, Graduate School of Medicine, The University of Tokyo – sequence: 12 givenname: Shinichi surname: Yamauchi fullname: Yamauchi, Shinichi organization: Department of Surgical Oncology, Graduate School of Medicine, The Tokyo Medical and Dental University – sequence: 13 givenname: Kenichi surname: Sugihara fullname: Sugihara, Kenichi organization: Department of Surgical Oncology, Graduate School of Medicine, The Tokyo Medical and Dental University – sequence: 14 givenname: Soichiro surname: Ishihara fullname: Ishihara, Soichiro organization: Department of Surgical Oncology, Graduate School of Medicine, The University of Tokyo |
BackLink | https://cir.nii.ac.jp/crid/1870020693313518080$$DView record in CiNii https://www.ncbi.nlm.nih.gov/pubmed/35501727$$D View this record in MEDLINE/PubMed |
BookMark | eNqNU9lq3DAUNSWlSdP8QB-KoKW0D061eJH7UAihiyFQ6PIsZFmeUdBIU0meLJ_XL-v1zDTJhBJqg22uzzlXOvfoabbnvNNZ9pzgY0J49S4SynmZY0pz3FSkzK8fZQekqElOC1zv3fnez45iNB3GlOOCNeWTbJ-VJSY1rQ-y36fWOKOkRWaxlCohP6BlMAsZrlAaFz6gaHrdOx0jkq5HUV8i79Dogo5aJdlZjZY-pjxoNYagndIojmFlVpOkQxuY7tFSprm3frbuFZOcadS2edu2SEE5TFoWKQn8EN8jiZxMxrsLaI4Wo01GaZd0AL0UfFwC3KygUxr7q2fZ40HaqI-278Ps56ePP06_5GdfP7enJ2e5qqs65X1REUYw4briquJVxxiuSTPUstMVBTNr0ks10KJRdcFw1ZSD7qmminNadXXJDrN2o9t7eS62JgkvjVgXfJgJGWChVgtedkTyCpe8KQpSy0aWuO4HPHQlGxrMQYtttEa3lFcX0tobQYLFNGCxGbCAAYv1gMU1sD5sWMuxW-h-siRIu7OU3T_OzMXMr0SDK0YbCgJvtgLB_xp1TGJhotLWSqf9GAWtygasYJQB9OU96LkfgwODAQUXbILRW9RMwraNGzz0VZOoOKkxZQXkrALU8T9QcPd6YRTkejBQ3yG83SEAJunLNJNjjKL9_m0X-_oOdq6lTfPo7TjFJ-4CX9x178a2v4cBAHQDUBCxGPTwfzPh90jKpHV2YY_GPkzdhiBCHzfT4dbiB1mvNixnDPSanoTXcLohsowRVhKOOWZ_AHFLSi4 |
CitedBy_id | crossref_primary_10_1002_ijc_34959 crossref_primary_10_3390_bios13030398 crossref_primary_10_3390_jcm13133654 crossref_primary_10_1093_bjsopen_zrad085 crossref_primary_10_1159_000539981 |
Cites_doi | 10.1200/JCO.2013.53.2473 10.1200/JCO.2009.23.3452 10.1056/NEJMoa0805019 10.1007/s00535-020-01706-7 10.1038/nm.3967 10.1016/S1470-2045(14)70330-4 10.1200/JCO.2005.205.60 10.1093/annonc/mdw235 10.1016/j.ejso.2015.01.035 10.1200/JCO.2000.18.2.412 10.1111/cas.14117 10.1186/s12957-017-1198-0 10.1097/DCR.0000000000001202 10.1038/srep29765 10.1158/1078-0432.CCR-17-2484 10.3322/caac.21660 10.1245/s10434-019-07164-7 10.1200/JCO.2009.27.4860 10.1111/j.1463-1318.2006.01017.x 10.1016/S1470-2045(16)30269-8 10.1001/jamaoncol.2017.1016 10.1136/ejhpharm-2018-001657 10.1007/s10147-019-01485-z 10.1245/s10434-019-07209-x 10.1038/s41467-019-13266-3 10.18632/oncotarget.19038 10.1111/ijcp.14863 10.1097/SLA.0000000000002206 10.4174/astr.2019.96.6.296 10.1016/j.ejca.2020.06.005 10.1002/(SICI)1097-0215(19960621)69:3<190::AID-IJC7>3.0.CO;2-V 10.1200/JCO.2009.27.6055 10.1016/j.ctro.2019.11.006 10.1093/annonc/mdu275 10.1001/jamaoncol.2016.4227 10.1016/j.cell.2017.07.008 10.1186/s12885-016-2412-0 10.1200/JCO.2009.21.9170 10.1093/annonc/mdx175 10.1038/nri.2016.90 10.1016/j.clcc.2020.08.007 10.1016/j.ejca.2017.07.013 10.1200/JCO.2005.03.171 10.1159/000505128 10.1097/DCR.0b013e31823c08b3 |
ContentType | Journal Article |
Copyright | The Author(s) 2022 2022. The Author(s). COPYRIGHT 2022 BioMed Central Ltd. 2022. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
Copyright_xml | – notice: The Author(s) 2022 – notice: 2022. The Author(s). – notice: COPYRIGHT 2022 BioMed Central Ltd. – notice: 2022. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
DBID | RYH C6C AAYXX CITATION CGR CUY CVF ECM EIF NPM ISR 3V. 7TO 7X7 7XB 88E 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH H94 K9. M0S M1P PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 5PM ADTOC UNPAY DOA |
DOI | 10.1186/s12885-022-09615-z |
DatabaseName | CiNii Complete Springer Nature OA Free Journals (WRLC) CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Gale In Context: Science ProQuest Central (Corporate) Oncogenes and Growth Factors Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni Edition) ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central ProQuest One Community College ProQuest Central Korea Health Research Premium Collection Health Research Premium Collection (Alumni) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Health & Medical Collection (Alumni Edition) PML(ProQuest Medical Library) Proquest Central Premium ProQuest One Academic (New) Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) Unpaywall for CDI: Periodical Content Unpaywall DOAJ Directory of Open Access Journals |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database Oncogenes and Growth Factors Abstracts ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Central China ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Health & Medical Research Collection AIDS and Cancer Research Abstracts ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
DatabaseTitleList | MEDLINE Publicly Available Content Database MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: C6C name: Springer Nature OA Free Journals url: http://www.springeropen.com/ sourceTypes: Publisher – sequence: 2 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 3 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 4 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 5 dbid: UNPAY name: Unpaywall url: https://proxy.k.utb.cz/login?url=https://unpaywall.org/ sourceTypes: Open Access Repository – sequence: 6 dbid: BENPR name: ProQuest Central url: http://www.proquest.com/pqcentral?accountid=15518 sourceTypes: Aggregation Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1471-2407 |
EndPage | 10 |
ExternalDocumentID | oai_doaj_org_article_85b1a8605894417a9a507df0fb53f908 10.1186/s12885-022-09615-z PMC9063292 A702345016 35501727 10_1186_s12885_022_09615_z |
Genre | Multicenter Study Journal Article |
GeographicLocations | Japan |
GeographicLocations_xml | – name: Japan |
GrantInformation_xml | – fundername: Japan Society for the Promotion of Science,Japan grantid: C: grant number; 19K09115 – fundername: Japan Society for the Promotion of Science grantid: C: grant number; 18K07194 funderid: http://dx.doi.org/10.13039/501100001691 – fundername: Japan Society for the Promotion of Science grantid: C: grant number; 18K07194 – fundername: ; grantid: C: grant number; 18K07194 – fundername: ; grantid: C: grant number; 19K09115 |
GroupedDBID | --- 0R~ 23N 2WC 53G 5VS 6J9 6PF 7X7 88E 8FI 8FJ AAFWJ AAJSJ AASML AAWTL ABDBF ABUWG ACGFO ACGFS ACIHN ACMJI ACPRK ACUHS ADBBV ADRAZ ADUKV AEAQA AENEX AFKRA AFPKN AHBYD AHMBA AHYZX ALIPV ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIJS BAPOH BAWUL BCNDV BENPR BFQNJ BMC BPHCQ BVXVI C6C CCPQU CS3 DIK DU5 E3Z EAD EAP EAS EBD EBLON EBS EMB EMK EMOBN ESX F5P FYUFA GROUPED_DOAJ GX1 HMCUK HYE IAO IHR IHW INH INR ISR ITC KQ8 M1P M48 M~E O5R O5S OK1 OVT P2P PGMZT PHGZM PHGZT PIMPY PQQKQ PROAC PSQYO RBZ RNS ROL RPM RSV RYH SBL SOJ SV3 TR2 TUS U2A UKHRP W2D WOQ WOW XSB PJZUB PPXIY PUEGO AAYXX CITATION -A0 3V. ACRMQ ADINQ C24 CGR CUY CVF ECM EIF NPM PMFND 7TO 7XB 8FK AZQEC DWQXO H94 K9. PKEHL PQEST PQUKI PRINS 7X8 5PM 2VQ 4.4 ADTOC AHSBF C1A EJD H13 IPNFZ LGEZI LOTEE NADUK NXXTH RIG UNPAY |
ID | FETCH-LOGICAL-c767t-d46131018e68c686b330719f7abe6228871dacf249c7430695fed2e2c8826b753 |
IEDL.DBID | M48 |
ISSN | 1471-2407 |
IngestDate | Wed Aug 27 01:24:42 EDT 2025 Wed Aug 20 00:20:47 EDT 2025 Tue Sep 30 15:31:03 EDT 2025 Fri Sep 05 04:12:27 EDT 2025 Fri Jul 25 21:39:04 EDT 2025 Tue Jun 17 21:21:43 EDT 2025 Tue Jun 10 20:28:38 EDT 2025 Fri Jun 27 04:16:02 EDT 2025 Thu May 22 20:53:43 EDT 2025 Thu Jan 02 22:54:18 EST 2025 Thu Apr 24 22:57:45 EDT 2025 Wed Oct 01 05:06:52 EDT 2025 Sat Sep 06 07:18:36 EDT 2025 Thu Jun 26 23:11:53 EDT 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 1 |
Keywords | Primary tumor location Chemoradiotherapy Outcome Prognostic marker Colorectal cancer |
Language | English |
License | 2022. The Author(s). Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. cc-by |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c767t-d46131018e68c686b330719f7abe6228871dacf249c7430695fed2e2c8826b753 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
OpenAccessLink | https://link.springer.com/10.1186/s12885-022-09615-z |
PMID | 35501727 |
PQID | 2666608332 |
PQPubID | 44074 |
PageCount | 10 |
ParticipantIDs | doaj_primary_oai_doaj_org_article_85b1a8605894417a9a507df0fb53f908 unpaywall_primary_10_1186_s12885_022_09615_z pubmedcentral_primary_oai_pubmedcentral_nih_gov_9063292 proquest_miscellaneous_2659228323 proquest_journals_2666608332 gale_infotracmisc_A702345016 gale_infotracacademiconefile_A702345016 gale_incontextgauss_ISR_A702345016 gale_healthsolutions_A702345016 pubmed_primary_35501727 crossref_primary_10_1186_s12885_022_09615_z crossref_citationtrail_10_1186_s12885_022_09615_z springer_journals_10_1186_s12885_022_09615_z nii_cinii_1870020693313518080 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2022-05-02 |
PublicationDateYYYYMMDD | 2022-05-02 |
PublicationDate_xml | – month: 05 year: 2022 text: 2022-05-02 day: 02 |
PublicationDecade | 2020 |
PublicationPlace | London |
PublicationPlace_xml | – name: London – name: England |
PublicationTitle | BMC Cancer |
PublicationTitleAbbrev | BMC Cancer |
PublicationTitleAlternate | BMC Cancer |
PublicationYear | 2022 |
Publisher | Springer Science and Business Media LLC BioMed Central BioMed Central Ltd BMC |
Publisher_xml | – name: Springer Science and Business Media LLC – name: BioMed Central – name: BioMed Central Ltd – name: BMC |
References | GW Ha (9615_CR6) 2019; 26 D Arnold (9615_CR21) 2017; 28 JM Lee (9615_CR29) 2019; 96 V Heinemann (9615_CR17) 2014; 15 WA Messersmith (9615_CR12) 2019; 17 Y Yamada (9615_CR45) 2019; 110 AM Kaiser (9615_CR25) 2006; 8 S Malakorn (9615_CR10) 2021; 20 S Stintzing (9615_CR18) 2016; 17 S Meltzer (9615_CR32) 2020; 21 S Haupt (9615_CR24) 2019; 10 AD Roth (9615_CR38) 2010; 28 T Yu (9615_CR34) 2017; 170 RX Zhang (9615_CR3) 2017; 15 F Petrelli (9615_CR5) 2017; 3 C Radkiewicz (9615_CR42) 2017; 84 Japanese Society for Cancer of the Colon and Rectum (9615_CR49) 2005 JM Loree (9615_CR39) 2018; 24 SL Klein (9615_CR41) 2016; 16 9615_CR44 S Karim (9615_CR7) 2017; 3 J Liu (9615_CR23) 2020; 27 J Benhattar (9615_CR40) 1996; 69 D Shida (9615_CR28) 2020; 55 S Singh (9615_CR47) 2005; 23 R Warschkow (9615_CR8) 2016; 16 K Matsuda (9615_CR2) 2020; 98 H Sung (9615_CR1) 2021; 71 H Li (9615_CR27) 2017; 8 E Van Cutsem (9615_CR14) 2009; 360 JA Sloan (9615_CR43) 2000; 18 S Ishihara (9615_CR9) 2018; 267 E Missiaglia (9615_CR35) 2014; 25 Y Hashiguchi (9615_CR13) 2020; 25 CJ Allegra (9615_CR37) 2009; 27 A Athauda (9615_CR46) 2020; 137 E Van Cutsem (9615_CR11) 2016; 27 Z Gao (9615_CR33) 2015; 6 MF Kalady (9615_CR22) 2012; 55 J Guinney (9615_CR36) 2015; 21 M Riihimäki (9615_CR31) 2016; 6 K Westberg (9615_CR26) 2015; 41 JY Douillard (9615_CR15) 2010; 28 B Klimm (9615_CR48) 2005; 23 LS Schwartzberg (9615_CR16) 2014; 32 D Shida (9615_CR4) 2019; 26 CALGB/SWOG (9615_CR19) 2006; 4 M Peeters (9615_CR20) 2010; 28 CL Sparreboom (9615_CR30) 2018; 61 |
References_xml | – volume: 32 start-page: 2240 issue: 21 year: 2014 ident: 9615_CR16 publication-title: J Clin Oncol doi: 10.1200/JCO.2013.53.2473 – volume: 28 start-page: 466 issue: 3 year: 2010 ident: 9615_CR38 publication-title: J Clin Oncol doi: 10.1200/JCO.2009.23.3452 – volume: 360 start-page: 1408 issue: 14 year: 2009 ident: 9615_CR14 publication-title: N Engl J Med doi: 10.1056/NEJMoa0805019 – volume: 55 start-page: 958 issue: 10 year: 2020 ident: 9615_CR28 publication-title: J Gastroenterol doi: 10.1007/s00535-020-01706-7 – volume: 21 start-page: 1350 issue: 11 year: 2015 ident: 9615_CR36 publication-title: Nat Med doi: 10.1038/nm.3967 – volume: 15 start-page: 1065 issue: 10 year: 2014 ident: 9615_CR17 publication-title: Lancet Oncol doi: 10.1016/S1470-2045(14)70330-4 – volume: 23 start-page: 8003 issue: 31 year: 2005 ident: 9615_CR48 publication-title: J Clin Oncol doi: 10.1200/JCO.2005.205.60 – volume: 27 start-page: 1386 issue: 8 year: 2016 ident: 9615_CR11 publication-title: Ann Oncol doi: 10.1093/annonc/mdw235 – volume: 41 start-page: 659 issue: 5 year: 2015 ident: 9615_CR26 publication-title: Eur J Surg Oncol doi: 10.1016/j.ejso.2015.01.035 – volume: 18 start-page: 412 issue: 2 year: 2000 ident: 9615_CR43 publication-title: J Clin Oncol doi: 10.1200/JCO.2000.18.2.412 – volume: 110 start-page: 2875 issue: 9 year: 2019 ident: 9615_CR45 publication-title: Cancer Sci doi: 10.1111/cas.14117 – volume: 4 start-page: 452 issue: 6 year: 2006 ident: 9615_CR19 publication-title: Clin Adv Hematol Oncol – volume: 15 start-page: 138 issue: 1 year: 2017 ident: 9615_CR3 publication-title: World J Surg Oncol doi: 10.1186/s12957-017-1198-0 – volume: 61 start-page: 1258 issue: 11 year: 2018 ident: 9615_CR30 publication-title: Dis Colon Rectum doi: 10.1097/DCR.0000000000001202 – volume: 17 start-page: 599 issue: 5.5 year: 2019 ident: 9615_CR12 publication-title: J Natl Compr Cancer Netw – volume: 6 start-page: 29765 year: 2016 ident: 9615_CR31 publication-title: Sci Rep doi: 10.1038/srep29765 – volume: 24 start-page: 1062 issue: 5 year: 2018 ident: 9615_CR39 publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-17-2484 – volume: 71 start-page: 209 issue: 3 year: 2021 ident: 9615_CR1 publication-title: CA Cancer J Clin doi: 10.3322/caac.21660 – volume: 26 start-page: 1366 issue: 5 year: 2019 ident: 9615_CR6 publication-title: Ann Surg Oncol doi: 10.1245/s10434-019-07164-7 – volume: 28 start-page: 4697 issue: 31 year: 2010 ident: 9615_CR15 publication-title: J Clin Oncol doi: 10.1200/JCO.2009.27.4860 – volume: 8 start-page: 696 issue: 8 year: 2006 ident: 9615_CR25 publication-title: Color Dis doi: 10.1111/j.1463-1318.2006.01017.x – volume: 17 start-page: 1426 issue: 10 year: 2016 ident: 9615_CR18 publication-title: Lancet Oncol doi: 10.1016/S1470-2045(16)30269-8 – volume: 3 start-page: 1386 issue: 10 year: 2017 ident: 9615_CR7 publication-title: JAMA Oncol doi: 10.1001/jamaoncol.2017.1016 – volume: 27 start-page: 267 issue: 5 year: 2020 ident: 9615_CR23 publication-title: Eur J Hosp Pharm doi: 10.1136/ejhpharm-2018-001657 – volume: 25 start-page: 1 issue: 1 year: 2020 ident: 9615_CR13 publication-title: Int J Clin Oncol doi: 10.1007/s10147-019-01485-z – volume: 6 start-page: 20 year: 2015 ident: 9615_CR33 publication-title: Front Microbiol – volume: 26 start-page: 1358 issue: 5 year: 2019 ident: 9615_CR4 publication-title: Ann Surg Oncol doi: 10.1245/s10434-019-07209-x – volume: 10 start-page: 5385 issue: 1 year: 2019 ident: 9615_CR24 publication-title: Nat Commun doi: 10.1038/s41467-019-13266-3 – volume: 8 start-page: 89203 issue: 51 year: 2017 ident: 9615_CR27 publication-title: Oncotarget doi: 10.18632/oncotarget.19038 – ident: 9615_CR44 doi: 10.1111/ijcp.14863 – volume: 267 start-page: 917 issue: 5 year: 2018 ident: 9615_CR9 publication-title: Ann Surg doi: 10.1097/SLA.0000000000002206 – volume: 96 start-page: 296 issue: 6 year: 2019 ident: 9615_CR29 publication-title: Ann Surg Treat Res doi: 10.4174/astr.2019.96.6.296 – volume: 137 start-page: 45 year: 2020 ident: 9615_CR46 publication-title: Eur J Cancer doi: 10.1016/j.ejca.2020.06.005 – volume: 69 start-page: 190 issue: 3 year: 1996 ident: 9615_CR40 publication-title: Int J Cancer doi: 10.1002/(SICI)1097-0215(19960621)69:3<190::AID-IJC7>3.0.CO;2-V – volume: 28 start-page: 4706 issue: 31 year: 2010 ident: 9615_CR20 publication-title: J Clin Oncol doi: 10.1200/JCO.2009.27.6055 – volume: 21 start-page: 5 year: 2020 ident: 9615_CR32 publication-title: Clin Transl Radiat Oncol doi: 10.1016/j.ctro.2019.11.006 – volume-title: JSCCR guidelines 2005 for the treatment of colorectal Cancer year: 2005 ident: 9615_CR49 – volume: 25 start-page: 1995 issue: 10 year: 2014 ident: 9615_CR35 publication-title: Ann Oncol doi: 10.1093/annonc/mdu275 – volume: 3 start-page: 211 issue: 2 year: 2017 ident: 9615_CR5 publication-title: JAMA Oncol doi: 10.1001/jamaoncol.2016.4227 – volume: 170 start-page: 548 issue: 3 year: 2017 ident: 9615_CR34 publication-title: Cell doi: 10.1016/j.cell.2017.07.008 – volume: 16 start-page: 554 year: 2016 ident: 9615_CR8 publication-title: BMC Cancer doi: 10.1186/s12885-016-2412-0 – volume: 27 start-page: 2091 issue: 12 year: 2009 ident: 9615_CR37 publication-title: J Clin Oncol doi: 10.1200/JCO.2009.21.9170 – volume: 28 start-page: 1713 issue: 8 year: 2017 ident: 9615_CR21 publication-title: Ann Oncol doi: 10.1093/annonc/mdx175 – volume: 16 start-page: 626 issue: 10 year: 2016 ident: 9615_CR41 publication-title: Nat Rev Immunol doi: 10.1038/nri.2016.90 – volume: 20 start-page: e53 issue: 1 year: 2021 ident: 9615_CR10 publication-title: Clin Colorectal Cancer doi: 10.1016/j.clcc.2020.08.007 – volume: 84 start-page: 130 year: 2017 ident: 9615_CR42 publication-title: Eur J Cancer doi: 10.1016/j.ejca.2017.07.013 – volume: 23 start-page: 850 issue: 4 year: 2005 ident: 9615_CR47 publication-title: J Clin Oncol doi: 10.1200/JCO.2005.03.171 – volume: 98 start-page: 230 issue: 4 year: 2020 ident: 9615_CR2 publication-title: Oncology doi: 10.1159/000505128 – volume: 55 start-page: 128 issue: 2 year: 2012 ident: 9615_CR22 publication-title: Dis Colon Rectum doi: 10.1097/DCR.0b013e31823c08b3 |
SSID | ssib002804395 ssj0017808 |
Score | 2.3887541 |
Snippet | Background
Several studies have demonstrated that right-sided tumors have poorer prognosis than left-sided tumors in patients with unresectable colorectal... Several studies have demonstrated that right-sided tumors have poorer prognosis than left-sided tumors in patients with unresectable colorectal cancer (CRC).... Background Several studies have demonstrated that right-sided tumors have poorer prognosis than left-sided tumors in patients with unresectable colorectal... Abstract Background Several studies have demonstrated that right-sided tumors have poorer prognosis than left-sided tumors in patients with unresectable... |
SourceID | doaj unpaywall pubmedcentral proquest gale pubmed crossref springer nii |
SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 486 |
SubjectTerms | Adenocarcinoma Antigens Biomedical and Life Sciences Biomedicine Cancer Research Cancer therapies Cecum Chemoradiotherapy Chemotherapy Colorectal cancer Colorectal carcinoma Colorectal Neoplasms Colorectal Neoplasms - drug therapy Colorectal Neoplasms - pathology Colorectal Neoplasms - surgery Drug therapy Evaluation Female Females Health Promotion and Disease Prevention Humans Liver Lymph nodes Lymphatic Metastasis Lymphatic system Male Males Medical prognosis Medicine/Public Health Metastases Metastasis Mutation Neoplasm Recurrence, Local Neoplasm Recurrence, Local - epidemiology Neoplasm Recurrence, Local - pathology Neoplasm Staging Neoplasms. Tumors. Oncology. Including cancer and carcinogens Oncology Outcome Patients Peritoneum Physiological aspects Primary tumor location Prognosis Prognostic marker Radiation therapy RC254-282 Retrospective Studies Review boards Sex Sex factors in disease Surgery Surgical Oncology Surveillance Survival Tumors |
SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3LbtUwELWgCx4LxJtACwYhsaBR83QcdgVRNUhlAVTqznJsp1zpklR5UOjn8WXM2EloBCos2NxFMkmu7fHx8WPOEPJcG5gzlIHxTaWNDyOE8fMoKHERJ5BGhzrgGOB88J7tHybvjtKjc6m-8EyYkwd2FbfD0zKUHDfvcsyWJXMJDEZXQVWmcZW7MF8YxqbJ1Lh_kPGATyEynO10gMIcI5EjH1OcpP7ZYhiyav0zJl-uV6s_8c3fj03Oe6fXydWhPpHfT-V6fW542rtJboy8ku668twil0x9m1w5GHfO75AfowDomrq4SNpU9MQpTdB--NK0FPN2agQ-KmtNO_ONNjUdrBqQ6jHAip40Xe-3uEBvQwRpNwDOfMVX1tSZGU0xxfEEqBSo57GhReEXRUFRHxvxFa4r9LW2e0UldauRp_Bxag83YrFNC-_r22YKA6VWBPcuOdx7--nNvj_mb_BVxrLe1wlwBVQEM4wrxlkZA6CEeZXJ0rAIWiQLtVQVTAAV8JiA5WlldGQiBayflTCPukc26qY2DwhNNFMmKXkaqTJJecVjaVCpLTOpzLK49Eg4NadQo7g55thYCzvJ4Uw4FxDgAsK6gDjzyMv5mbHCL7R-jV4yW6Ist70AzipGZxV_c1aPPEEfEy7GdQYXsZsBdUpSoN8eeWYtUJqjxrM_x3LoOlF8_LAwejEaVQ2UUskxlALqCtW8FpabC0vADrW4vQXODjWGvyFAN0weWB7HmLYRBUfh8akbiBHbOgGUjjFg7nHkkafzbXwznterTTOgTZqjsFIUe-S-6zVzzQHDxYWHzCPZoj8tqnZ5p159tsrnORDqKIfvbk8979ffuqjptufe-Q8t_fB_tPQjci2ycIOos0k2-nYwW0Bf-_KxRaqfd8STbQ priority: 102 providerName: Directory of Open Access Journals – databaseName: Health & Medical Collection dbid: 7X7 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1Lb9QwELZokXgcEG8CLRiExIFGzWPjOFxQQVRdpHIAKvVmObazrLQkSx4U-vP4Zcw4TkoEWnHZQzJJ1vb48-fHfEPIc21gzpAHxjeFNj6MEMbPoiDHRZxAGh3qgGOA8_EHdnQye3-anLoFt8Ydqxww0QK1rhSuke_DQMIY8IU4er3-5mPWKNxddSk0tsjlEKgKenV6Ok64wpQHfAiU4Wy_ASzmGI8c-ZjoJPHPJ4OR1ewfkXmrXC7_xTr_Pjw57qBeJ1e7ci1_nsnV6o9B6vAmueHYJT3o3eEWuWTK2-TKsds_v0N-ORnQFe2jI2lV0HWvN0Hb7mtVU8zeqRH-qCw1bcwPWpW0s5pAqsUwK7qumtavcZneBgrSpgO0-Y6vLGlvZjTFRMcDrFIgoAtD53N_Pp9TVMlGlIXrCj2ubl5RSfs1yTP4OLVHHLHYpob3tXU1BINSK4V7l5wcvvv89sh3WRx8lbK09fUMGAPqghnGFeMsjwFWwqxIZW5YBC2ShlqqAqaBCthMwLKkMDoykQLuz3KYTd0j22VVmgeEzjRTZpbzJFL5LOEFj6VBvbbUJDJN49wj4dCcQjmJc8y0sRJ2qsOZ6F1AgAsI6wLi3CMvx2dchW-0foNeMlqiOLe9UNUL4fq64EkeSo77zRkmeJOZBNKti6DIk7jIAu6RJ-hjoo90HSFGHKRAoGYJkHCPPLMWKNBR4gmgheyaRsw_fZwYvXBGRQWlVNIFVEBdoabXxHJnYgkIoia3d8HZocbwNwQAhykEy-IYkzei7Cg8PnQD4RCuERf90SNPx9v4Zjy1V5qqQ5skQ3mlKPbI_b7XjDUHPBeXH1KPpJP-NKna6Z1y-cXqn2dAq6MMvrs39LyLv7Wp6fbG3vkfLf1wc6EfkWuRBRLEkx2y3dad2QV62uaPLQb9Bq9Xi-A priority: 102 providerName: ProQuest – databaseName: SpringerLink Journals (ICM) dbid: U2A link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Jb9QwFLZokVgOiJ1ACwYhcaARWR2H24CoGqRyAEbqzXJsZxhpSEZZKPTn8ct4z1kgoqrgMofk2ZnYz18-L-97hDzXBuYMuWdcU2jjwhfCuGng5biI40mjfe1xDHA-_sCOltH7k_hkCAprxtPu45akRWo7rDl71QCScowmDlxMUxK7ZzvkcowOBF68DBbT3kHCPT6Gx5xbbvYJskr9Ex7vlOv1eVzz7yOT077pdXK1K7fyx6ncbP74NB3eJDcGTkkXvRPcIpdMeZtcOR52ze-Qn4P454b2MZG0Kui2V5mgbfe1qinm7NQIelSWmjbmO61K2lklINVicBXdVk3r1rg4b8MDadMBxnzDKkvamxlNMb3xCKYUaOfK0CxzsyyjqI2N2ArXFfpZ3bymkvYrkafwcGoPNuJrmxrqa-tqDAGlVgD3Llkevvv89sgdcje4KmFJ6-oIeAKqgRnGFeMsDwFM_LRIZG5YAD2S-FqqAiZ_CjiMx9K4MDowgQLGz3KYQ90ju2VVmgeERpopE-U8DlQexbzgoTSo0paYWCZJmDvEH7tTqEHYHPNrbISd4HAmehcQ4ALCuoA4c8jLqczQ4Bdav0EvmSxRktteqOqVGEa44HHuS467zCmmdZOpBKqtC6_I47BIPe6QJ-hjoo9vnYBFLBKgTVEM1Nshz6wFynKUeO5nJbumEdmnjzOjF4NRUcFbKjmEUUBboZLXzHJvZgm4oWa398HZocXw1wfYhokDS8MQUzai2CgUH4eBGHCtEUDnGAPWHgYOeTrdxprxrF5pqg5t4hRFlYLQIff7UTO1HLBbXHRIHJLMxtOsaed3yvUXq3qeApkOUnjuwTjyfv-ti7ruYBqd_9DTD_-v9kfkWmCBBfFlj-y2dWf2gaS2-WOLSb8AM2eJfQ priority: 102 providerName: Springer Nature – databaseName: Unpaywall dbid: UNPAY link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Zb9QwELZKK3E8cB-BFgxC4oGmzbFxEt4KouoitUJApfJk-UpZdZusclDoz-OXMeMcNFBVIPGyWsUTJxl7Po-P-YaQ59rAnEF6xjWZNi6MEMZNA0_iIo4njPa1l2CA8-4e29mfvDuIDpbITh8LI4-xSmXKjbPh53OL2fBHHW0udNaaesI2K0DXBCOMAxdTl0Tu6SWywnCraZms7O-93_psg4tiHzcR4j5m5twbR-OSpe8fQPpSPpud54D-eY5y2Ey9Rq40-UJ8PxHz-ZnxavsGmfVf2h5TOdpoarmhTn8jgfwfqrhJrndOLd1qe-EtsmTy2-Tybrdtf4f86NhH57QNyqRFRhctzQWtm-OipJg0VCPqUpFrWplvtMhpY6mIVI3RXXRRVLVb4u6AjU-kVQMg9xWrzGkrZjTF_Mo9mlPwew8NnU7d6XRKkZwbwR2ut59bvaKCtkuhJ_Bwak9W4sebEuqry6KPQaWWgfcu2d9---nNjtslj3BVzOLa1RNwVJCOzLBEsYTJENDMT7NYSMMC0FXsa6EymH0qcKI8lkaZ0YEJFEw5mIRJ3D2ynBe5eUDoRDNlJjKJAiUnUZIloTBIExebSMRxKB3i912Hq45ZHRN8zLmdYSWMt43DoXG4bRx-6pCXwz2dwi-Ufo09cpBETnB7oSgPeQcxPImkLxLc5k4xr5xIBfj6OvMyGYVZ6iUOeYL9mbcBtgOy8a0Y_LZJBL6_Q55ZCeQFyfHg0aFoqopPP34YCb3ohLICu6Ho4jhAV0glNpJcHUkCcKlR8RoYFmgMf30YN2DmwtIwxJyRyHYKt_cmxztgrTj4k2DfSRgGDnk6FGPNeFgwN0WDMlGKrE5B6JD7rYUOmgP3Glc9YofEI9sdqXZcks--WNr1FLz5IIXnrvdW_uu1Lmq69QEJ_qKlH_6b-CNyNbAmj5a_SpbrsjFr4CXX8nEHgD8BgUG1Tw priority: 102 providerName: Unpaywall |
Title | Clinical impact of primary tumor sidedness and sex on unresectable post-recurrence survival in resected pathological stage II-III colorectal cancers: a nationwide multicenter retrospective study |
URI | https://cir.nii.ac.jp/crid/1870020693313518080 https://link.springer.com/article/10.1186/s12885-022-09615-z https://www.ncbi.nlm.nih.gov/pubmed/35501727 https://www.proquest.com/docview/2666608332 https://www.proquest.com/docview/2659228323 https://pubmed.ncbi.nlm.nih.gov/PMC9063292 https://bmccancer.biomedcentral.com/track/pdf/10.1186/s12885-022-09615-z https://doaj.org/article/85b1a8605894417a9a507df0fb53f908 |
UnpaywallVersion | publishedVersion |
Volume | 22 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
journalDatabaseRights | – providerCode: PRVADU databaseName: BioMed Central Open Access Free customDbUrl: eissn: 1471-2407 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0017808 issn: 1471-2407 databaseCode: RBZ dateStart: 20010101 isFulltext: true titleUrlDefault: https://www.biomedcentral.com/search/ providerName: BioMedCentral – providerCode: PRVAFT databaseName: Open Access Digital Library customDbUrl: eissn: 1471-2407 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0017808 issn: 1471-2407 databaseCode: KQ8 dateStart: 20010101 isFulltext: true titleUrlDefault: http://grweb.coalliance.org/oadl/oadl.html providerName: Colorado Alliance of Research Libraries – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 1471-2407 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0017808 issn: 1471-2407 databaseCode: DOA dateStart: 20010101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVEBS databaseName: EBSCOhost Academic Search Ultimate customDbUrl: https://search.ebscohost.com/login.aspx?authtype=ip,shib&custid=s3936755&profile=ehost&defaultdb=asn eissn: 1471-2407 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0017808 issn: 1471-2407 databaseCode: ABDBF dateStart: 20010101 isFulltext: true titleUrlDefault: https://search.ebscohost.com/direct.asp?db=asn providerName: EBSCOhost – providerCode: PRVBFR databaseName: Free Medical Journals customDbUrl: eissn: 1471-2407 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0017808 issn: 1471-2407 databaseCode: DIK dateStart: 20010101 isFulltext: true titleUrlDefault: http://www.freemedicaljournals.com providerName: Flying Publisher – providerCode: PRVFQY databaseName: GFMER Free Medical Journals customDbUrl: eissn: 1471-2407 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0017808 issn: 1471-2407 databaseCode: GX1 dateStart: 0 isFulltext: true titleUrlDefault: http://www.gfmer.ch/Medical_journals/Free_medical.php providerName: Geneva Foundation for Medical Education and Research – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources (selected full-text only) customDbUrl: eissn: 1471-2407 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0017808 issn: 1471-2407 databaseCode: M~E dateStart: 20010101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre – providerCode: PRVAQN databaseName: PubMed Central customDbUrl: eissn: 1471-2407 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0017808 issn: 1471-2407 databaseCode: RPM dateStart: 20010101 isFulltext: true titleUrlDefault: https://www.ncbi.nlm.nih.gov/pmc/ providerName: National Library of Medicine – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 1471-2407 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0017808 issn: 1471-2407 databaseCode: 7X7 dateStart: 20090101 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: http://www.proquest.com/pqcentral?accountid=15518 eissn: 1471-2407 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0017808 issn: 1471-2407 databaseCode: BENPR dateStart: 20090101 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVFZP databaseName: Scholars Portal Journals: Open Access customDbUrl: eissn: 1471-2407 dateEnd: 20250930 omitProxy: true ssIdentifier: ssj0017808 issn: 1471-2407 databaseCode: M48 dateStart: 20010801 isFulltext: true titleUrlDefault: http://journals.scholarsportal.info providerName: Scholars Portal – providerCode: PRVAVX databaseName: HAS SpringerNature Open Access 2022 customDbUrl: eissn: 1471-2407 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0017808 issn: 1471-2407 databaseCode: AAJSJ dateStart: 20011201 isFulltext: true titleUrlDefault: https://www.springernature.com providerName: Springer Nature – providerCode: PRVAVX databaseName: Springer Nature OA Free Journals customDbUrl: eissn: 1471-2407 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0017808 issn: 1471-2407 databaseCode: C6C dateStart: 20011201 isFulltext: true titleUrlDefault: http://www.springeropen.com/ providerName: Springer Nature – providerCode: PRVAVX databaseName: SpringerLink Journals (ICM) customDbUrl: eissn: 1471-2407 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0017808 issn: 1471-2407 databaseCode: U2A dateStart: 20011201 isFulltext: true titleUrlDefault: http://www.springerlink.com/journals/ providerName: Springer Nature |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1Zb9QwELZ6SBwPiJtAuxiExAMN5LQdJITaqlUXqVVVWKnwYjmJUyotSckBbX8ev4wZ5ygRVdUXS5tMnI0983l8zDeEvEo1zBliR9s6S7UNI4S2I8-JcRHHUTp1U0dggPPuHtuZBZ8Ow8MF0qc76hqwunRqh_mkZuX87enPs49g8B-MwQv2rgKMFRhn7NmYwCS0zxfJMoxMHmr5bnCxq8CFyVDnAiDjrgLvg2gurWM0UBk-_wG1F_Pj48s80v8PVg67q7fJzSY_UWe_1Xz-zwC2fZfc6TxPut6qyj2yoPP75MZut7f-gPzpKELntI2cpEVGT1ouClo3P4qSYmbPFKGRqjyllT6lRU4bwxeU1BiCRU-KqrZLXMI3QYS0agCJfmGVOW3FdEoxCXIPuRSc0yNNp1N7Op1SZNBGBIbrCWpjWb2nirbrlb_h5dQcf8TP1iXUV5dFHyhKDU3uQzLb3vqyuWN3GR7shDNe22kA3gRyhmkmEiZY7APkuFHGVayZBz3C3VQlGUwRE_B0HBaFmU497SUwL2AxzLQekaW8yPUTQoOUJTqIReglcRCKTPhKI5cb16Hi3I8t4vbdKZOO_hyzcMylmQYJJlsVkKAC0qiAPLfIm-GZrsGvlN5ALRkkkbjbXCjKI9nhgBRh7CqBe9ERJn9TkQKHPM2cLA79LHKERZ6jjsk2CnaAH7nOwbkKQnDQLfLSSCB5R46ng45UU1Vy-vlgJPS6E8oK-MpEdcEW0FbI9zWSXBlJAroko9uroOzQYli6AO4wvWCR72NiR6Qkhcd7M5C98Upw-hgD3973LPJiuI0144m-XBcNyoQRUi95vkUet1YztBz4wLg0wS3CR_Y0atrxnfz4u-FGj8Dl9iJ471pveRd_66quWxus8xo9_fTarfuM3PIMpiC0rJClumz0KnixdTwhi_yQT8jyxtbe_gH82mSbE7MiNDGgBeXBxjcoZx5cWZ7t7a9__QvC2J1A |
linkProvider | Scholars Portal |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwELZKkSgcEG8CLTUIxIFGzdN2kBAqj6qhjwO00t6MkzhlpSVZ8qC0P4ofwS9jJq8SgVZcetlDPEk29vibGdvzDSFPEw0xQ2RpU6eJNsFCaDNwrAgXcSylEzuxBCY47x-wnSPvw8SfLJGffS4MHqvsMbEB6iSPcY18EwwJY-AvuM7r-TcTq0bh7mpfQqNVi119egIhW_kqfAfj-8xxtt8fvt0xu6oCZswZr8zEAwuGPFWaiZgJFkFEz-0g5SrSzHFg0tmJilMIS2KwrhYL_FQnjnZi8EVZxLFKBED-ZWjykKufT4YAz-bCEn1ijmCbJWC_wPxnx8TCKr55NjJ-TY2AwRJcyqbTf3m5fx_WHHZsr5GVOpur0xM1m_1hFLdvkOudN0u3WvW7SZZ0dotc2e_262-TXx3t6Iy22Zg0T-m85begVf01LyhWC00QbqnKElrqHzTPaN1wEMUVpnXReV5WZoHbAk1iIi1rQLfv-MiMtmI6oVhYuYdxCg7vsaZhaIZhSJGVG1Edrseo4UX5kiraroGewMtpc6QSP1sX8LyqyPvkU9pQ794hRxcyvnfJcpZn-j6hXsJi7UXCd-LI80UqXKWRH45rX3HuRgax--GUcUepjpU9ZrIJrQSTrQpIUAHZqIA8M8iL4Z6uwxdKv0EtGSSRDLy5kBfHssMWKfzIVgL3twMsKKcCBU5-klpp5LtpYAmDrKOOyTazdoA0ucXBYfN8cPoN8qSRQEKQDE8cHau6LGX46eNI6HknlObwlbHqEjigr5BDbCS5OpIExIpHzWug7NBj-GuDwYCQhQWui8UikeYUbu-ngewQtZTn898gj4dmfDKeEsx0XqOMHyCdk-Ma5F47a4aeA78alzu4QfhoPo26dtySTb80fOsBuPFOAO_d6Gfe-d9aNHQbw-z8j5F-sPij18nKzuH-ntwLD3YfkqtOAyqILatkuSpqvQaucRU9avCIks8XDYC_Ae3vxto |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Jb9QwFLZoKxU4IHYCLTUIiQONmsniONyGpWoGWiFKpd4sx3aGkYZklIVCfx6_jPey0YiqgssckmdnYj9_-by87xHyQhuYMySOsU2qjQ1fCGNHrpPgIo4jjZ5oh2OA8-EROzjxZ6fB6YUo_ua0e78l2cY0oEpTVu2tdNoOcc72SkBVjpHFro0pSwL7fI1s8CBiMP3amE5nx7NhJyHkDu-DZS4tOfogNbr9AzqvZYvFZczz7wOUwy7qTXK9zlby55lcLi98qPZvk1sdw6TT1iXukGsmu0s2D7s99HvkVycFuqRthCTNU7pqNSdoVX_LC4oZPDVCIJWZpqX5QfOM1o0ukKow1Iqu8rKyC1yqb4IFaVkD4nzHKjPamhlNMdlxD60USOjc0Di24zimqJSNSAvXFXpdUb6mkrbrkmfwcNocc8TXNgXUVxV5HxBKGznc--Rk__2Xtwd2l8nBViELK1v7wBpQG8wwrhhniQfQMonSUCaGudAj4URLlcJUUAGjcVgUpEa7xlXA_1kCM6oHZD3LM_OIUF8zZfyEB65K_ICn3JMGNdtCE8gw9BKLTPruFKqTOcdsG0vRTHc4E60LCHAB0biAOLfIq6FM1-BXWr9BLxksUaC7uZAXc9GNd8GDZCI57jlHmORNRhKIt06dNAm8NHK4RXbQx0Qb7TrAjJiGQKL8AIi4RZ43FijSkeEpoLmsy1LEx59HRi87ozSHt1SyC6qAtkJdr5Hl1sgSUESNbm-Ds0OL4e8EQBymESzyPEzgiNKjULwfBqJDuVIAuWMMOLznWuTZcBtrxpN7mclrtAkilFhyPYs8bEfN0HLAdXEJIrRIOBpPo6Yd38kWXxsN9AiotRvBc3f7kffnb13VdbvD6PyHnn78f7XvkM1P7_bFx_jowxNyw20wBqFmi6xXRW22gb1WydMOoH4DDgmR-w |
linkToUnpaywall | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Zb9QwELZKK3E8cB-BFgxC4oGmzbFxEt4KouoitUJApfJk-UpZdZusclDoz-OXMeMcNFBVIPGyWsUTJxl7Po-P-YaQ59rAnEF6xjWZNi6MEMZNA0_iIo4njPa1l2CA8-4e29mfvDuIDpbITh8LI4-xSmXKjbPh53OL2fBHHW0udNaaesI2K0DXBCOMAxdTl0Tu6SWywnCraZms7O-93_psg4tiHzcR4j5m5twbR-OSpe8fQPpSPpud54D-eY5y2Ey9Rq40-UJ8PxHz-ZnxavsGmfVf2h5TOdpoarmhTn8jgfwfqrhJrndOLd1qe-EtsmTy2-Tybrdtf4f86NhH57QNyqRFRhctzQWtm-OipJg0VCPqUpFrWplvtMhpY6mIVI3RXXRRVLVb4u6AjU-kVQMg9xWrzGkrZjTF_Mo9mlPwew8NnU7d6XRKkZwbwR2ut59bvaKCtkuhJ_Bwak9W4sebEuqry6KPQaWWgfcu2d9---nNjtslj3BVzOLa1RNwVJCOzLBEsYTJENDMT7NYSMMC0FXsa6EymH0qcKI8lkaZ0YEJFEw5mIRJ3D2ynBe5eUDoRDNlJjKJAiUnUZIloTBIExebSMRxKB3i912Hq45ZHRN8zLmdYSWMt43DoXG4bRx-6pCXwz2dwi-Ufo09cpBETnB7oSgPeQcxPImkLxLc5k4xr5xIBfj6OvMyGYVZ6iUOeYL9mbcBtgOy8a0Y_LZJBL6_Q55ZCeQFyfHg0aFoqopPP34YCb3ohLICu6Ho4jhAV0glNpJcHUkCcKlR8RoYFmgMf30YN2DmwtIwxJyRyHYKt_cmxztgrTj4k2DfSRgGDnk6FGPNeFgwN0WDMlGKrE5B6JD7rYUOmgP3Glc9YofEI9sdqXZcks--WNr1FLz5IIXnrvdW_uu1Lmq69QEJ_qKlH_6b-CNyNbAmj5a_SpbrsjFr4CXX8nEHgD8BgUG1Tw |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Clinical+impact+of+primary+tumor+sidedness+and+sex+on+unresectable+post-recurrence+survival+in+resected+pathological+stage+II-III+colorectal+cancers%3A+a+nationwide+multicenter+retrospective+study&rft.jtitle=BMC+cancer&rft.au=Abe%2C+Shinya&rft.au=Kawai%2C+Kazushige&rft.au=Nozawa%2C+Hiroaki&rft.au=Sasaki%2C+Kazuhito&rft.date=2022-05-02&rft.pub=BioMed+Central+Ltd&rft.issn=1471-2407&rft.eissn=1471-2407&rft.volume=22&rft.issue=1&rft_id=info:doi/10.1186%2Fs12885-022-09615-z&rft.externalDocID=A702345016 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1471-2407&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1471-2407&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1471-2407&client=summon |